Riskpilot← Back to searchSign inGet full accessNUTRIPHARMA INTERNATIONAL AS
ASActiveOrg 922251096Kyrkjevegen 45, 6230 SykkylvenWholesale of other food · NACE 4638Est. 20190 employees
Revenue 2024
NOK 0
EBITDA margin
—
+43% vs 2023
Equity ratio
99.5%
Financial strength
Net profit 2024
NOK -17K
+96% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -70K | +43% |
| Net profit | NOK -17K | +96% |
| Total assets | NOK 3,5M | -63% |
| Equity | NOK 3,5M | +0% |
| Employees | 0 | — |
Legal name
NUTRIPHARMA INTERNATIONAL AS
Org number
922251096
Legal form
Aksjeselskap
NACE code
4638 · Wholesale of other food
Founded
19. februar 2019
Share capital
NOK 750 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder eller styrets leder hver for seg.
Company purpose
Investeringsvirksomhet, og andre produkter/tjenester som naturlig hører sammen med dette, kjøp og salg av alle typer verdipapirer og herunder å delta i andre selskap.
Address
Kyrkjevegen 45, 6230 Sykkylven
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 50 | 530 | 0 | 0 |
| Staff expenses | −0 | −1 550 | −492 | −0 | −0 |
| EBITDA | −21 | −1 720 | −134 | −124 | −70 |
| Depreciation & amort. | −0 | −10 | −0 | −0 | −0 |
| EBIT | −21 | −1 731 | −134 | −124 | −70 |
| Net financials | −560 | −60 | 915 | −346 | 54 |
| Profit before tax | −581 | −1 791 | 782 | −470 | −17 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −581 | −1 791 | 782 | −470 | −17 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 30 | 5 535 | 8 169 | 9 471 | 3 528 |
| Equity | 8 | 3 217 | 3 999 | 3 529 | 3 512 |
| Long-term debt | 0 | 119 | 0 | 0 | 0 |
| Short-term debt | 22 | 2 200 | 4 171 | 5 943 | 16 |
| Total debt | 22 | 2 318 | 4 171 | 5 943 | 16 |
EBITDA margin
-7033900.0%
This company
15.8%
Market median
-44518454% vs market
20202024
Equity ratio
99.5%
This company
38.2%
Market median
+160% vs market
20202024
Return on equity
-0.5%
This company
18.4%
Market median
-103% vs market
20202024
Net profit margin
-1675000.0%
This company
8.1%
Market median
-20679112% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RM Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2025 | |
| Former (4) | ||
| Chairman | 2022 – 2025 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Chairman | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharma Norge As
NUTRIPHARMA INTERNATIONAL AS Board members of NUTRIPHARMA INTERNATIONAL AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rune Meyer | Chief Executive Officer | 0 companies |
| Svein Erik Nicolaysen | Chairman | 0 companies |
| Thomas Kristoffer Storvestre | Chairman | 0 companies |
| Lars Ola Engebretsen Annexstad | Board of Directors | 0 companies |
| Aasmund Olav Brevik | Board of Directors | 0 companies |
| Anders Lindstad | Chairman | 0 companies |